New Rule Gives Force to Ground-Breaking State 340B Contract Pharmacy Law

Arkansas Insurance Department 340B drug program rules document
Arkansas has published a regulation that gives force to the state’s ground-breaking 340B contract pharmacy law.

The Arkansas Insurance Department (AID) published a rule this week that gives force to the state’s ground-breaking 2021 law prohibiting drug makers from denying 340B pricing or restricting access to drugs when covered entities contract with pharmacies to dispense 340B

Read More »

Merck Announces Third Round of 340B Refunds for 2019 Drug Purchases

Merck corporate campus signage
Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.

Drug manufacturer Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.

The latest round covers 15 NDCs sold during Q3 2019. The previously announced refunds were for sales during Q1

Read More »

HRSA Grants 340B Enrollment Flexibility in Puerto Rico Due to Hurricane

Puerto Rico, Hurricane Fiona, Pedro Pierluisi and other officials assess damage
Puerto Rico Gov. Pedro Pierluisi (D) (second from right), FEMA officials, and local residents assessed damage yesterday from Hurricane Fiona.

UPDATE Thursday, Sept. 22, 2022, 1:00 p.m. EDT—This story was updated to include new information from HRSA.


The U.S. Health Resources and Services Administration (HRSA) is letting eligible healthcare providers in Puerto Rico enroll in the 340B

Read More »

CMS Gets Conflicting Advice About Unwinding Drug Payment Cuts for 340B Hospitals

outpatient surgery center entrance sign on building facade
Stakeholders offered CMS conflicting advice about how to reverse a nearly 30% cut in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs since 2018. | Flickr.com/photos/rxb

Key stakeholders have offered federal healthcare officials conflicting advice about how best to respond to the U.S. Supreme Court’s June decision striking down a nearly 30% cut in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs.

Tuesday was the

Read More »

Unichem Says 340B Audit Found it Overcharged Just Two Entities and Must Repay Them Just $110.20

Drug manufacturer Unichem wordmark on building
Generic drug manufacturer Unichem says a 340B compliance audit found it overcharged just two entities and the repayment to both totals just $110.20.

Late last month, the U.S. Health Resources and Services Administration (HRSA) said on its website that generic drug manufacturer Unichem Pharmaceuticals USA had to repay 340B covered entities for overcharges found during a 340B program compliance audit.

According to Unichem,

Read More »

Comments Due Today on How Feds Should Rectify Drug Payment Cuts for 340B Hospitals

image of a calendar showing September 2022
Today is the deadline for public comments on Medicare’s proposed rule for how it will pay for hospital outpatient services and clinician-administered drugs in 2023.

Today is the deadline for public comments on Medicare’s proposed rule for how it will pay for hospital outpatient services and clinician-administered drugs in 2023.

340B stakeholders will be paying close attention to comments on how Medicare Part B should

Read More »

Restoring 340B Hospitals’ Part B Drug Payments Would Cut Net Outpatient Payments for 80% of Hospitals, Private Cancer Doctor-Funded Study Finds

Outpatient exterior sign on hospital
80% of hospitals in Medicare’s outpatient prospective payment system would see their net payments decline next year if CMS ends a nearly 30% cut in 340B hospitals’ drug payments, according to a private oncologist group funded study.

Eighty percent of all hospitals in Medicare’s outpatient prospective payment system—including 52% of all 340B hospitals—would see their net OPPS payments decline next year if Medicare ends a nearly 30% cut in 340B hospitals’ drug payments that began in 2018,

Read More »

Senior HRSA Official Pedley to Deliver ASHP’s Prestigious William A. Zellmer Lecture Next Week

Rear Admiral Krista Pedley saluting
Rear Adm. Krista Pedley, director of HRSA's Office of Special Health Initiatives, addressed the 340B patient definition at a conference Tuesday.

U.S. Public Health Service Rear Adm. Krista Pedley, a top official at the Health Resources and Services Administration (HRSA) and former longtime head of the 340B drug pricing program, has been selected by the American Society of Health-System Pharmacists (ASHP)

Read More »

Federal Health Officials with Significant 340B History Play Major Roles in CDC Revamp

Mary Wakefield, James Macrae headshots
Ex-HRSA Administrator Mary Wakefield and current HRSA Associate Administrator are playing pivotal roles in the U.S. Centers for Disease Control and Prevention overhaul.

Two federal health officials with long track records managing key aspects of the 340B program are playing pivotal roles in a major overhaul of the U.S. Centers for Disease Control and Prevention.

CDC Director Rochelle Walensky last month named Mary

Read More »

News Alert

Becerra Says Legislation Is Needed to Strengthen HHS Authority to Address 340B Contract Pharmacy Pricing Denials

Xavier Becerra speaking to the press
Congress needs to give HHS more more regulatory power and money if its wants the department to do more about drug companies that curtail the use of 340B drugs in contract pharmacies, HHS Secretary Xavier Becerra told House members in a Sept. 1 letter.

U.S. Health and Human Services Secretary Xavier Becerra told members of Congress on Thursday that his department is doing all it can with the tools it has to address drug manufacturers’ denials of 340B pricing involving contract pharmacies.

If lawmakers

Read More »
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live